Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 3

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 3
---
-for-one basis.

This prospectus also includes the shares of common stock issuable upon exercise of the Pre-Funded Warrants. See “Description of Securities We Are Offering” in this prospectus for more information.

Our common stock trades on the Nasdaq Capital Market under the symbol “SHPH.” On February 26, 2025, the last reported sale price of our common stock was $0.60 per share.

We have retained WestPark Capital, Inc. as the exclusive underwriter with respect to this offering (the “Underwriter”). We have agreed to pay the underwriter fees totaling 4.0% of the aggregate gross cash proceeds actually realized by the Company from the sale of the shares being offered hereby. See “Underwriting” beginning on page 42 of this prospectus for more information regarding these arrangements.

You should read this prospectus, together with additional information described under the heading “Where You Can Find More Information,” carefully before you invest in any of our securities.

We are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), and we have elected to comply with certain reduced public company reporting requirements.

You should read this prospectus, together
with the additional information described under the headings “Where You Can Find More Information” and “Incorporation
of Documents by Reference,” carefully before you invest in any of our securities.

An investment in our securities involves significant risks. You should carefully consider the risk factors beginning on page 13 of this prospectus and in documents incorporated by reference into this prospectus before you make your decision to invest in our securities.

Neither the Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                 |     | Per  Share |     | Per Pre-Funded Warrant |     | Total(2) |
|:--------------------------------|:----|:-----------|:----|:-----------------------|:----|:---------|
| Public offering price           |     | $          |     |                        |     | $        |
| Underwriting discounts          
 and commissions(1)              |     | $          |     |                        |     | $        |
| Proceeds to us, before expenses |     | $          |     |                        |     | $        |

| (1) | We